Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

Source: genomeweb, February 2021

In a new clinical validation study, an international team led by investigators at NYU Langone Health has demonstrated that BRAF gene mutations detected in cell-free circulating tumor DNA (ctDNA) can offer a window into treatment response and potential outcomes in individuals with melanoma.

“Our findings suggest that levels of ctDNA may serve as a fast and reliable tool to gauge whether an anticancer medication is working,” senior author David Polsky, a pathology researcher at NYU Langone, said in a statement, noting that a blood test based on such ctDNA-based markers “could help support continuing the current treatment strategy or else encourage patients and physicians to consider other options.”